BIO-TECHNE Corp. 10-Q Summary: Fiscal Q2 2025
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2024 (Fiscal Q2 2025) and the six months ended December 31, 2024. BIO-TECHNE Corp. operates in two segments: Protein Sciences and Diagnostics and Spatial Biology. The company develops and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $297.0 million | $272.6 million | $586.5 million | $549.5 million |
| Gross Margin | $193.9 million (65.3%) | $176.6 million (64.8%) | $376.9 million (64.3%) | $361.8 million (65.8%) |
| Operating Income | $47.4 million | $38.0 million | $87.4 million | $93.9 million |
| Net Earnings | $34.9 million | $27.5 million | $68.5 million | $78.5 million |
| Diluted EPS | $0.22 | $0.17 | $0.42 | $0.49 |
| Cash & Equivalents | $177.5 million | Balance Sheet Data as of Dec 31, 2024 | ||
| Long-Term Debt | $300.0 million |
Liquidity: The company maintains a $1 billion revolving credit facility with $700 million available as of December 31, 2024. Operating cash flow for the six months ended December 31, 2024, was $148.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 9% in Q2 and 7% YTD compared to the prior year, driven by organic growth of 9% (Q2) and 7% (YTD). Growth was broad-based across the Diagnostics and Spatial Biology portfolio and improving biopharma conditions in Protein Sciences.
- Profitability: Q2 net earnings increased 27% year-over-year, primarily due to volume leverage and the absence of a non-recurring impairment charge recorded in the prior year. However, YTD net earnings decreased 13% due to significant restructuring costs.
- Restructuring Costs: The company incurred $13.2 million in restructuring and restructuring-related charges YTD 2025 (vs. $11.4 million YTD 2024). This includes $10.2 million in asset-related charges (impairments) and $3.1 million in employee severance.
- Segment Performance:
- Protein Sciences: Sales up 7% (Q2) and 3% (YTD). Operating margin improved to 41.2% in Q2.
- Diagnostics and Spatial Biology: Sales up 12% (Q2) and 13% (YTD). Operating margin was 3.9% in Q2.
Guidance, Outlook, and Risks
- Outlook: Management expects capital expenditures for the remainder of fiscal 2025 to be approximately $20 million. The forecasted GAAP tax rate for the remainder of fiscal 2025 is expected to range from 23% to 27% (excluding discrete items).
- Investments: The company invested $15 million in Spear Bio in July 2024. It also holds a forward contract to acquire the remaining 80.1% of Wilson Wolf Corporation, with a potential payment of approximately $1 billion triggered by future revenue/EBITDA milestones (forecasted between fiscal 2026 and 2028).
- Legal Matters: The company recognized $1.4 million in litigation charges in Q2. A dispute regarding the expiration of 794,400 vested stock options (valued at approx. $32 million) is under review; the company currently cannot estimate future exposure.
- Non-GAAP Measures: Adjusted net earnings for Q2 were $68.1 million ($0.42 diluted EPS), excluding restructuring, stock-based compensation, and amortization of intangibles.
Investor Verification Checklist
- Restructuring Impact: Verify the cash vs. non-cash nature of the $13.2 million YTD restructuring charge and its impact on future operating margins.
- Wilson Wolf Milestones: Monitor Wilson Wolf's revenue and EBITDA performance against the thresholds that would trigger the ~$1 billion acquisition payment.
- Stock Option Dispute: Track the resolution of the expired stock option dispute involving ~$32 million in value to assess potential liability.
- Organic Growth Sustainability: Confirm if the 9% Q2 organic growth rate is sustainable given the mix of consumables vs. instruments.
- Debt Utilization: Review the utilization of the $1 billion credit facility, currently at $300 million outstanding.